The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other healthcare professionals in making medical necessity and other coverage determinations. Please note the terms of a customer’s particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy.

In the event of a conflict, a customer’s benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of:

1. The terms of the applicable benefit plan document in effect on the date of service
2. Any applicable laws and regulations
3. Any relevant collateral source materials including coverage policies
4. The specific facts of the particular situation

Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines.

This evidence-based medical coverage policy has been developed by eviCore, Inc. Some information in this coverage policy may not apply to all benefit plans administered by Cigna.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2018 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

©Copyright 2019 eviCore healthcare
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMM-209.1: Definitions</td>
<td>3</td>
</tr>
<tr>
<td>CMM-209.2: General Guidelines</td>
<td>3</td>
</tr>
<tr>
<td>CMM-209.3: Indications</td>
<td>3</td>
</tr>
<tr>
<td>CMM-209.4: Non-Indications</td>
<td>4</td>
</tr>
<tr>
<td>CMM-209.5: Procedure (CPT®) Codes</td>
<td>4</td>
</tr>
<tr>
<td>CMM-209.6: References</td>
<td>5</td>
</tr>
</tbody>
</table>
CMM-209.1: Definitions

- **Regional sympathetic blocks** (i.e., stellate ganglion blocks and lumbar sympathetic blocks) refer to the injection of local anesthetic along the sympathetic ganglia under fluoroscopy to reduce sympathetic nervous system activity. A diagnostic regional sympathetic block is considered positive when there is significant reduction in pain and improvement in function for the duration of the local anesthetic used.

- **Complex Regional Pain Syndrome (CRPS)** is defined by the International Association for the Study of Pain (IASP) as a variety of painful conditions following injury which appear regionally having a distal predominance of abnormal findings, exceeding in both magnitude and duration the expected clinical course of the inciting event and often resulting in significant impairment of motor function, and showing variable progression over time. In addition to injury, CRPS can also occur as a result of various medical disorders or illnesses.

CMM-209.2: General Guidelines

- The determination of medical necessity for the performance of regional sympathetic blocks is always made on a case-by-case basis.

- **Please note:** this guideline does not apply to injections.blocks of other autonomic nerves (e.g., sphenopalatine ganglion, carotid sinus, superior hypogastric plexus, celiac plexus blocks, Gasserian ganglion [trigeminal nerve], splanchnic nerve, Ganglion of Impar, rami communicans).

- Regional sympathetic blocks should be performed using fluoroscopy.

- Due to insufficient evidence that regional sympathetic blocks (stellate ganglion blocks and lumbar sympathetic chain blocks) performed as an isolated treatment alter the long term outcome of CRPS, all regional sympathetic blocks in recalcitrant cases of CRPS should be performed with the intent of facilitating involvement and advancement in an active rehabilitation/functional restoration program.

CMM-209.3: Indications

- The performance of an initial diagnostic regional sympathetic block is considered **medically necessary** to establish the presence or absence of sympathetically mediated complex regional pain syndrome. A positive response is defined as at least 50% reduction in pain and improvement in function for the duration of the local anesthetic used.

- Following a successful initial diagnostic block, three (3) additional therapeutic regional sympathetic blocks, performed within the first two (2) weeks of the initial block, may be considered **medically necessary** to diagnose the individual’s pain and obtain a therapeutic response.
Additional therapeutic regional sympathetic blocks are considered **medically necessary** when provided as part of a comprehensive pain management program and **ALL** of the following criteria are met:
- Decreased use of pain medication
- Increased functional ability (e.g., increased range of motion, strength, and use of the extremity in activities of daily living)
- Increased tolerance to touch (e.g., decreased allodynia)
- Ongoing participation in an active rehabilitation program
- Performed at a frequency of no more than one time per week
- No more than six (6) total blocks.

**CMM-209.4: Non-Indications**
- Regional sympathetic blocks are considered **not medically necessary** for each of the following:
  - When the individual is not capable of participating or is not involved in an ongoing, active rehabilitation program
  - Without the use of fluoroscopic guidance
  - No significant reduction in pain and no improvement in function for the duration of local anesthetic following the diagnostic block
  - A repeat therapeutic block when there is no decrease in use of pain medication, increase in functional ability, and increase of tolerance to touch

**CMM-209.5: Procedure (CPT®) Codes**

<table>
<thead>
<tr>
<th>CPT®</th>
<th>Code Description/Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>64510</td>
<td>Injection, anesthetic agent; stellate ganglion (cervical sympathetic)</td>
</tr>
<tr>
<td>64520</td>
<td>Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic)</td>
</tr>
</tbody>
</table>

This guideline relates to the CPT® code set below. Codes are displayed for informational purposes only. Any given code's inclusion on this list does not necessarily indicate prior authorization is required.

This list may not be all inclusive and is not intended to be used for coding/billing purposes. The final determination of reimbursement for services is the decision of the health plan and is based on the individual's policy or benefit entitlement structure as well as claims processing rules.
CMM-209.6: References


